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ABSTRAK 
Latar belakang 
Tuberkulosis merupakan satu daripada penyakit utama dunia, membabitkan kira-
kira satu pertiga daripada penduduk dunia. Pengenalan ubat antituberkulosis beberapa 
dekad yang lalu telah memperbaiki nasib pesakit yang dijangkiti tuberculosis dengan 
sebaiknya. Di antara ubatan antituberkulosis, isoniazid, rifampicin dan pyrazinamide 
telah terbukti berkesan, tetapi bukan tanpa kesan sampingan, seperti keracunan hati. 
Hepatitis disebabkan ubat antituberkulosis telah banyak dilaporkan dan banyak faktor-
faktor risiko telah dikesan. 
Objektif 
Kajian kes kawalan dan pemerhatian ini dijalankan untuk memastikan 
kewujudan hepatitis disebabkan ubat antituberkulosis di Hospital Universiti Sains 
Malaysia, memastikan faktor-faktor risiko hepatitis disebabkan ubat antituberkulosis 
dan memerhati perkembangan klinikal pesakit yang menghidapi hepatitis. 
Metod 
Kajian ini memeriksa bukti-bukti hepatitis disebabkan ubat antituberkulosis di 
kalangan pesakit yang dirawat sebagai tuberkulosis di Klinik Dada sepanjang 30 bulan 
daripada Januari 2003 hingga Jun 2005. Kes-kes hepatitis disebabkan ubat 
antituberkulosis yang layak dipilih dan dibandingkan dengan pesakit kawalan yang 
dipilih secara Sampel Rawak Mudah dari segi data demografi dan faktor risiko yang 
terlibat seperti umur, jantina, indeks jisim badan, pembawa hepatitis B, jangkitan HIV, 
tempat tuberkulosis dan fungsi biokimia hati seperti albumin, globulin, AST, AL T dan 
bilirubin. Perkembangan klinikal pesakit yang menghidapi hepatitis diperiksa dari segi 
xu 
pennulaan, keterukan dan jangkamasa hepatitis serta adanya jaWldis. Data dianalisis 
menggunakan khi square dan ujian t bebas (univariasi) dan analisis regresi binari 
logistik (multivariasi). 
Keputusan 
Sejumlah 473 pesakit didaftarkan sepanjang tempoh kajian, 46 orang 
daripadanya dikesan menghidapi hepatitis disebabkan ubat antituberkulosis dan layak 
untuk kajian. 13 8 pesakit lain dipilih sebagai kawalan. Prevalens hepatitis disebabkan 
ubat ialah 9. 7 peratus. Daripada faktor-faktor risiko yang dianalisis, jangkitan HIV 
(p=0.05) dan tuberkulosis ekstrapulmonari (p=0.008), tahap albumin serum rendah 
(p=0.023) dan tahap globulin tinggi (p=0.025) dikesan signifikan dalam analisis 
univariasi. Dalam analisis regresi logistik binari, jangkitan HIV (p=O.Ol8) dan 
tuberkulosis ekstrapulmonari (p=O.Ol7) dikesan sebagai faktor risiko yang signifikan. 
Pemerhatian perkembangan klinikal pesakit yang mengalami hepatitis menunjukkan 
kebanyakannya menghidapi hepatitis ringan (58.7%) dan sederhana (32.6%). Permulaan 
hepatitis kebanyakannya berlaku dalam satu hingga dua minggu (32.6%) dan dua 
hingga tiga minggu (17.4%). Tempoh hepatitis kebanyakannya dalam masa seminggu 
(34.8%) sehingga dua minggu (32.6%). Jaundis berlaku kepada 32.6 peratus pesakit. 
Rumusan 
Prevalens hepatitis disebabkan ubat antituberkulosis ialah 9.7 peratus. Jangkitan 
HIV dan tuberkulosis ekstrapulmonari merupakan faktor-faktor risiko terjadinya 
hepatitis. Kebanyakan pesakit mengalami simptom dan tanda hepatitis yang ringan. 
Pesakit yang mempunyai faktor risiko perlu diperhati secara teliti berkaitan terjadinya 
hepatitis disebabkan ubat antituberkulosis. 
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ABSTRACT 
Background 
Tuberculosis is one of the major diseases worldwide, affecting about one-third of 
the world's population. The introduction of antituberculosis drugs decades ago has 
improved tremendously the outcome of those infected with tuberculosis. Among the 
drugs, isoniazid, rifampicin and pyrazinamide had been proven to be effective, but not 
without the side effects, of which hepatotoxicity is the most important. Antituberculosis 
drug-induced hepatitis has been reported and many risk factors had been recognized. 
Objectives 
This case control and observational study was conducted to determine the 
prevalence of antituberculosis drug-induced hepatitis in Hospital Universiti Sains 
Malaysia, to determine the risk factors in relation to the development of drug-induced 
hepatitis as well to observe the clinical course in patients with antituberculosis drug-
induced hepatitis. 
Method 
This study examined the evidence of antituberculosis drug-induced hepatitis in 
patients treated for tuberculosis in Chest Clinic for a period of 30 months from January 
2003 until June 2005. Eligible cases of drug-induced hepatitis were selected and 
compared with controls which were selected by Simple Random Sampling in terms of 
demographic data and risks involved such as age, gender, body mass index, hepatitis B 
carrier, HIV infection, sites of tuberculosis, and pretreatment liver biochemistries such 
as serum albumin, globulin, AST, AL T and bilirubin. The clinical course of patients of 
hepatitis was also examined in term of onset, severity and duration of hepatitis, as well 
xiv 
as the presence of jaundice. Data were evaluated by k.hi square and independent t test 
(univariate) and binary logistic regression analysis (multivariate). 
Results 
A total of 4 73 patients were registered dwing the period of the study, 46 patients 
were noted to have antituberculosis drug-induced hepatitis and eligible for the study. 
138 patients were selected as controls. The prevalence of drug-induced hepatitis was 
9.7%. Among the risk factors evaluated, the presence of HIV infection (p=0.05), 
extrapulmonary tuberculosis (p=0.08), lower serum albumin (p=0.023) and higher 
serum globulin (p=0.025) were noted to be significant at univariate analysis. On binary 
logistic regression analysis, the presence of HIV infection (p=O.O 18) and 
extrapulmonary tuberculosis (p=0.017) were noted to be significant risk factors. 
Observation of the clinical course of patients who had drug-induced tuberculosis, 
showed that most of them had mild hepatitis (58.7%) and moderate hepatitis (32.6%). 
The onset of hepatitis mostly occurred between one to two weeks (32.6%) and two to 
three weeks (17.4%). The duration of hepatitis was mostly from one week (34.8%) to 
two weeks (32.6% ). The occurrence of jaundice was 32.6 percent. 
Conclusion 
The prevalence of antituberculosis drug-induced hepatitis was 9. 7 percent. The 
presence of HIV infection and extrapulmonary tuberculosis were significant risk factors 
for the development of hepatitis. Most of the patients who developed antituberculosis 
drug-induced hepatitis had mild symptoms and signs. Patients with risk factors should 
be monitored closely for the development of drug-induced hepatitis. 
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CHAPTER ONE 
INTRODUCTION 
1. INTRODUCTION 
1.1 Tuberculosis 
1.1.1 Background 
CHAPTER ONE: INTRODUCTION 
Tuberculosis, one of the oldest diseases known to affect humans, is caused by 
bacteria belonging to the Mycobacterium tuberculosis complex. The disease usually 
affects the lungs, although, in up to one-third of cases other organs are also involved. 
Transmission usually takes place through air-borne spread of droplet nuclei produced by 
patients with infectious pulmonary tuberculosis (Kasper DL et al, 2005). 
1.1.2 Aetiologic Agent 
Mycobacteria belong to the family Mycobacteriaceae and the order 
Actinomycetales. Among the pathogenic species belonging to the M tuberculosis 
complex, the most frequent and important agent of human disease is M tuberculosis. 
The complex includes M bovis, M africanum, M microti and M canettii. 
M tuberculosis is a rod-shaped, non-spore forming, thin aerobic bacterium and 
is often neutral on Gram's staining. However, once stained, the bacilli cannot be 
decolourized by acid alcohol, a characteristic called 'acid-fast bacilli'. Acid fastness is 
due mainly to the organisms' high content of mycolic acid, long-chain cross-linked fatty 
acids, and other cell-wall lipids (Kasper DL et al, 2005). 
1 
1.1.3 Epidemiology 
Tuberculosis is a worldwide pandemic. In recent years the incidence of 
tuberculosis has been rising, ranking this disease as one of the major threats to public 
health (Snider DE & Roper WL, 1992). 
In 2003, 8.8 million new tuberculosis cases were reported globally. Overall, one 
third of the world's population is currently infected with M tuberculosis with global 
incidence growing at one percent per year. Nearly two million deaths are reported every 
year due to tuberculosis, with most of them (98%) occurring in the developing world 
affecting mostly young adults in their most productive years (WHO, 2005). 
The largest number of cases occur in the South-East Asian Region, which 
accounts for 33 percent of the global prevalence. However, the estimated incidence per 
capita in sub-Saharan Africa is nearly twice that of South-East Asia, at 350 cases per 
100,000 population (WHO, 2005). 
In Malaysia, for the year 1999, 14,908 new cases of tuberculosis were reported, 
with the majority of them occurring in the economically productive age group (15-50 
years old) (Ministry of Health Malaysia, 2002). Latest estimates put Malaysia in the 46th 
place in the global rank by number of cases of tuberculosis. The incidence of new cases 
of tuberculosis is currently 47 per 100,000 population per year, with prevalence of all 
cases of 136 cases per 100,000 population. The tuberculosis mortality rates in Malaysia 
were estimated at 17 cases per 100,000 population per year (WHO, 2005). 
2 
1.1.4 Pathogenesis 
The interaction of M tuberculosis with the human host begins when droplet 
nuclei containing microorganisms from infectious patients are inhaled. While the 
majority of inhaled bacilli are trapped in the upper airways and expelled by ciliated 
mucosal cells, a fraction (usually less than 10%) reach the alveoli, where the bacilli are 
ingested by activated alveolar macrophages. 
In the initial stage of host-bacterium interaction, either the host's macrophages 
contain bacillary multiplication by producing proteolytic enzymes and cytokines, or the 
bacilli begin to multiply. If the bacilli multiply, their growth quickly kills the 
macrophages. Nonactivated monocytes later ingest the bacilli released from the lysed 
macrophages. These initial stages of infection are usually asymptomatic. 
About two to four weeks after infection, two additional host responses to M 
tuberculosis develop: a tissue-damaging response as a result of a delayed-type 
hypersensitivity reactions to various bacillary antigens which destroys nonactivated 
macrophages that contain multiplying bacilli; and a macrophage-activating response 
that is a cell-mediated phenomenon resulting in the activation of macrophages that are 
capable of killing and digesting tubercle bacilli. The balance between these two factors 
determines the form of tuberculosis that will develop subsequently (Kasper DL et al, 
2005). 
1.1.5 Clinical Manifestations 
Tuberculosis is classified as pulmonary or extrapulmonary depending upon the 
sites involved. 
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1.1.5(a) Pulmonary Tuberculosis 
Pulmonary tuberculosis can be categorized as prunary or postprimary 
(secondary). 
l.l.S(a)(i) Primary Disease 
Primary pulmonary tuberculosis results from an initial infection with the 
tuberculosis bacilli. The lesion is usually situated peripherally either in the middle or 
lower lung zones and accompanied by hilar or paratracheal lymphadenopathy, which 
may not be detected radiographically. In the majority of cases, the lesion heals 
spontaneously and may later develop a small calcified nodule, the Ghon lesion. 
In children and immunocompromised patients, primary pulmonary tuberculosis 
may progress rapidly to develop several clinical manifestations such as pleural effusio~ 
cavitation as well as hilar or mediastinal lymphadenopathy causing obstruction and 
subsequent lung collapse. Haematogenous spread may disseminate into various organs, 
where they may produce granulomatous lesions. Immunocompromised patients may 
later develop miliary tuberculosis and tuberculous meningitis (Kasper DL et al, 2005). 
l.l.S(a)(ii) Postprimary Disease 
Postprimary disease results from endogenous reactivation of latent infection and 
is usually localized to the apical and posterior segments of the upper lobes, where the 
high oxygen concentration favours mycobacterial growth. The superior segments of the 
lower lobes are also frequently involved. The extent of lung parenchymal involvement 
varies, from small infiltrates to extensive cavitary disease. 
4 
Early manifestations are often non-specific and insidious, consisting mainly of 
fever, night sweats, weight loss, anorexia and malaise. In the majority of cases, cough 
eventually develops, initially non-productive and subsequently purulent, with 
haemoptysis frequently documented. 
Physical findings may reveals crepitations and rhonchi over affected areas but 
frequently no abnormality would be detected. Haematologically, there would be mild 
anaemia with leucocytosis (Kasper DL et al, 2005). 
1.1.5(b) Extrapulmonary Tuberculosis 
This is mainly due to lympho-haematogenous dissemination during primary 
tuberculosis infection. The most commonly involved sites in extrapulmonary 
tuberculosis are the lymph nodes, pleura, genitourinary tract, bones and joints, meninges, 
gastrointestinal and peritoneum, as well as pericardium. However, virtually all organ 
systems may be affected (Kasper DL et al, 2005). Symptoms are often non-specific, 
including lassitude, anorexia, fever, and weight loss. Specific features will relate to the 
organs involved. 
1.1.5(b )(i) Tuberculous Lymphadenitis 
Tuberculous lymphadenitis is the most common presentation of extrapulmonary 
tuberculosis (documented in more than 25% of cases) and particularly frequent among 
HIV -infected patients. 
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It presents as painless swelling of lymph nodes, most commonly at cervical and 
supraclavicular sites. Systemic symptoms are usually limited to mv -infected patients. 
The diagnosis is established by fme-needle aspiration or surgical biopsy. AFB are seen 
in up to 50 percents of cases, cultures are positive in 70-80 percents, and histologic 
examination shows granulomatous lesions {Kasper DL et al, 2005). 
1.1.5(b )(ii) Pleural Tuberculosis 
Pleural tuberculosis results from penetration by tuberculosis bacilli into the 
pleural space. Symptoms such as fever, pleuritic chest pain and dyspnoea may occur, 
depending upon the extent of reactivity. Clinical and chest radiograph findings are those 
of pleural effusion. 
Thoracocentesis is required to ascertain the nature of the effusion. AFB are very 
rarely seen on direct smear, but cultures may be positive forM tuberculosis in up to 
one-third of cases. Pleural biopsy is often required for diagnosis and may reveal 
granulomas. It may yield a positive culture in up to 70 percents of cases (Kasper DL et 
al, 2005). 
1.1.5(b)(iii) Tuberculosis of the Upper Airways 
Tuberculosis of the upper airways may involve the larynx, pharynx and epiglottis, 
and nearly always a complication of advanced cavitary pulmonary tuberculosis. 
Symptoms include hoarseness, dysphagia as well as chronic productive cough. Sputum 
for AFB is often positive, but biopsy may be necessary in some cases to establish the 
diagnosis (Kasper DL et al, 2005). 
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l.l.S(b )(iv) Genitourinary Tuberculosis 
This accounts for approximately 15 percent of all extrapulmonary tuberculosis 
and is usually due to haematogenous seeding following primary infection. Common 
presentations are urinary frequency, dysuria, haematuria and flank pain, but patient may 
be asymptomatic. Urinalysis reveals pyuria and haematuria in nearly 90 percent of the 
cases. The documentation of culture-negative pyuria in acidic urine raises the suspicion 
of tuberculosis. 
Genital tuberculosis is more common in female, which affects the fallopian tubes 
and endometrium, and may cause infertility, pelvic pain as well as menstrual 
abnormalities. Diagnosis requires biopsy or culture of specimens obtained by dilatation 
and curettage. In male patients, the epididymis is often affected (Kasper DL et al, 2005). 
l.l.S(b )(v) Skeletal Tuberculosis 
Tuberculosis of the bones and joints is responsible for approximately 10 percent 
of extrapulmonary cases. It is related to reactivation of haematogenous foci or to spread 
from adjacent paravertebral lymph nodes. Weight-bearing joints (spines, hips and knees) 
are commonly affected. It may produce pain and swelling at the affected site. 
Diagnosis is confirmed by aspiration of the abscess or bone biopsy as cultures 
are usually positive and histologic findings highly typical. Computed tomography (CT) 
scan and magnetic resonance imaging (MRI) reveals the characteristic lesion and may 
suggest its aetiology (Kasper DL et al, 2005). 
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l.l.S(b )(vi) Tuberculous Meningitis 
Tuberculous meningitis accounts for five percent of extrapulmonary cases, seen 
most often in young children but also develop in adults, especially those who are 
infected with HIV. Tuberculous meningitis results from the haematogenous spread of 
primary or post-primary pulmonary disease or from rupture of a subependymal tubercle 
into the subarachnoid space. It may present subtly as headache and mental changes, or 
acutely as confusion, altered sensorium and neck rigidity. 
Lumbar puncture is the cornerstone of diagnosis and examination of 
cerebrospinal fluid (CSF) may reveal high leukocyte count and protein level with a low 
glucose concentration. AFB are seen on direct smear in 20 percent of cases, culture of 
CSF is positive in up to 80 percent of cases (Kasper DL et al, 2005). 
l.l.S(b )(vii) Gastrointestinal Tuberculosis 
Any portion of gastrointestinal tract may be affected by tuberculosis. Various 
pathogenetic mechanisms can be involved such as swallowing of sputum with direct 
seeding, haematogenous spread or rarely ingestion of bovine tuberculosis-infected milk. 
It commonly involves the terminal ileum and the caecum. The presentation includes 
abdominal pain, diarrhoea, haematochezia as well as fever, weight loss and night sweats. 
The diagnosis is usually by histologic examination and culture of specimens involved. 
Tuberculous peritonitis follows either the direct spread of tubercle bacilli from 
ruptured lymph nodes and intraabdominal organs or haematogenous seeding. Symptoms 
include nonspecific abdominal pain, fever and ascites. Paracentesis reveals an exudative 
8 
fluid with a high protein content and leucocytosis that is usually lymphocytic. The yield 
of direct smear and culture is relatively low, hence peritoneal biopsy may be required to 
establish the diagnosis (Kasper DL et al, 2005). 
1.1.5(b )(viii) Pericardia) tuberculosis 
This is either due to direct progression of a primary focus within the pericardium, 
reactivation of a latent focus or to a rupture of adjacent lymph nodes, which is 
frequently seen in HIV -infected patients. The onset may be subacute, although an acute 
presentation of fever, dull retrostemal pain and a friction rub is also possible. Pericardia! 
effusion develops in many cases. 
Diagnosis is by pericardiocentesis, which may reveal haemorrhagic, exudative 
and high leukocytes effusion. Culture is positive in about 30 percent of cases, while 
biopsy has a higher yield (Kasper DL et al, 2005). 
1.1.5(b )(ix) Miliary Tuberculosis 
Miliary or disseminated tuberculosis is due to haematogenous spread of 
tuberculosis bacilli either due to recent infection or reactivation of old disseminated foci. 
Lesions are usually yellowish granulomas one to two mm in diameter that resemble 
millet seeds. Symptoms are non-specific and usually include fever, night sweats, 
anorexia and weight loss. Others may have respiratory or abdominal symptoms. 
Physical findings include hepatomegaly, splenomegaly, and lymphadenopathy. 
Fundoscopy may reveal choroidal tubercle in up to 30 percent of cases. 
9 
Chest radiograph may reveal a miliary reticulonodular pattern as well as large 
infiltrates, interstitial infiltrates and pleural effusion. A sputum smear is negative in 80 
percent of cases and Mantoux test may be negative in up to 50 percent of cases. 
Bronchoalveolar lavage and transbronchial, liver or bone marrow biopsy may give 
higher yield (Kasper DL et al, 2005). 
1.1.5( c) HIV -Associated Tuberculosis 
Tuberculosis is an important opportunistic disease among HIV -infected patients 
worldwide. It can appear at any stage of HIV infection and its presentation varies with 
the stage. In partially immunocompromised patient, it presents as a typical pattern of 
upper lobe infiltrates and cavitation. In later stages, a primary tuberculosis-like pattern 
with diffuse interstitial or miliary infiltrates and intrathoracic lymphadenopathy, is more 
common. 
Extrapulmonary tuberculosis is common among HIV -infected patients. In 
various series, extrapulmonary tuberculosis - alone or in association with pulmonary 
disease- has been documented in 40 to 60 percent of all cases in HIV co-infected 
patients. The most common forms are lymphatic, disseminated, pleural and pericardia! 
as well as meningitis. 
The diagnosis of tuberculosis in HIV -infected patients may be difficult not only 
because of the increased frequency of sputum-smear negativity but also because of 
atypical radiographic findings, a lack of classic granuloma formation in the late stages 
and negative result in PPD skin tests (Kasper DL et al, 2005). 
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1.1.6 Diagnosis 
Diagnosis of tuberculosis is based on clinical, radiological and/or bacteriological 
evidence. 
1.1.6(a) AFB Microscopy 
This is based on the finding of AFB on microscopic examination of a diagnostic 
specimen such as sputum or tissue e.g. lymph node biopsy. 
1.1.6(b) Mycobacterial Culture 
Definitive diagnosis depends on the isolation and identification of M 
tuberculosis from a diagnostic specimen, usually sputum. Because most species of 
mycobacteria including M tuberculosis grow slowly, four to eight weeks may be 
required before growth is detected. 
1.1.6(c) Nucleic Acid Amplification 
This is based on amplification of mycobacterial nucleic acid. However, it is 
limited by low sensitivity and high cost. 
1.1.6(d) Radiography 
Classic picture of tuberculosis on chest x-ray is upper lobe infiltrates with 
cavitation. However, virtually any radiographic pattern - from a normal film or a 
solitary pulmonary nodule to diffuse alveolar infiltrates in a patient with Adult 
Respiratory Distress Syndrome (ARDS) - may be seen. In the era of AIDS, no 
radiographic pattern can be considered pathognomonic. 
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1.1.6(e) PPD Skin Test 
This test is used as a screening test for M tuberculosis infection, but it is limited 
by its low sensitivity and specificity. False negative reactions are common in 
immunocompromised patients and in those with overwhelming tuberculosis. Positive 
reactions are seen in patients infected with M tuberculosis and those who have been 
sensitized by nontuberculous mycobacteria or bacille Calmette-Guerin (BCG) 
vaccination. 
1.1.6(f) Other Diagnostic Procedures 
Other diagnostic procedures might be required in order to diagnose tuberculosis. 
This include bronchoscopy with bronchial brushings, bronchoalveolar lavage or 
trans bronchial biopsy. 
For patients suspected to have extrapulmonary tuberculosis, specimens from the 
involved sites may be required such as cerebrospinal fluid (CSF) in tuberculous 
meningitis, pleural fluid and biopsy for pleural disease, as well as bone marrow and 
liver biopsy in disseminated tuberculosis. 
1.1. 7 Treatment 
1.1.7(a) Aims 
The aims of treatment of tuberculosis include to reduce morbidity resulted from 
tuberculosis infection, to prevent mortality caused by tuberculosis, to prevent relapse of 
tuberculosis, to decrease transmission of tuberculosis to other people and to prevent the 
emergence of multidrug-resistant tuberculosis (Ministry of Health Malaysia, 2002). 
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1.1. 7(b) Chemotherapy 
Five drugs are considered essential (frrst-line) for the treatment of tuberculosis. 
These are isoniazid (H), rifampicin (R), pyrazinamide (Z), streptomycin (S) and 
ethambutol (E) (Ministry of Health Malaysia, 2002). More recently, streptomycin has 
been included as a second-line drug. Other second-line drugs include kanamycin, 
amikacin, capreomycin, ethionamide, cycloserine, p-Aminosalicylic acid (PAS), and 
fluoroquinolones such as ofloxacin, levofloxacin, gatifloxacin and moxifloxacin 
(Kasper DL et al, 2005). 
1.1. 7(b )(i) Isoniazid 
Isoniazid is a frrst-line agent for treatment for all forms of tuberculosis caused by 
organisms known or presumed to be susceptible to the drug. It has profound early 
bactericidal activity against rapidly dividing cells (Hafner R et al, 1997). 
The recommended dosage of isoniazid is 5-8 mg/kg for daily dosage, and 15-20 
mg/kg for biweekly dosage. 
1.1. 7(b )(ii) Rifampicin 
Rifampicin, also a first-line antituberculosis drug, has activity against organism 
that are dividing rapidly (early bactericidal activity) and against semidormant bacterial 
populations, thus accounting for its sterilizing activity (Dickinson JM & Mitchison DA, 
1981 ). It is an essential component of all short-course regimens. 
The recommended dosage of rifampicin is 10-15 mglkg for daily dosage, and 15-
20 mg/kg for biweekly dosage. 
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1.1. 7(b )(iii) Pyrazinamide 
Pyrazinamide, another frrst-line antituberculosis drug, exert greatest activity 
against the population of dormant or semidormant organisms contained within 
macrophages or the acidic environment of caseous foci (Girling DJ, 1984). 
The recommended ~ly dosage of pyrazinamide is 20-40 mg!kg. 
1.1. 7(b )(iv) Streptomycin 
Streptomycin and ethambutol have been shown to be approximately equivalent 
when used in the initial phase of treatment with 6-month regimens. However, among 
patients likely to have acquired M tuberculosis in a high-incidence country, it has 
relatively high rate of resistance. 
The recommended dosage of streptomycin is 15-20 mg!kg for daily dosage, and 
15-20 mg!kg for biweekly dosage. 
1.1.7(b)(v) Ethambutol 
Ethambutol is included in the initial treatment regimens primarily to prevent 
emergence of rifampicin resistance when primary resistance to isoniazid may be present 
(Blumberg HM et al, 2003). 
The recommended daily dosage of ethambutol is 15-25 mglkg. 
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1.1.7(c) Treatment Regimens 
Treatment regimens are divided into initial (or intensive) phase and continuation 
(or maintenance) phase (Ministry of Health Malaysia, 2002). 
1.1.7(c)(i) Intensive Phase 
During the intensive phase, three or four drugs are given daily. During this phase, 
the majority of the tubercle bacilli are killed, symptoms resolve and the patient becomes 
non-infectious (Kasper DL et al, 2005). This leads to rapid sputum conversion and 
amelioration of clinical symptoms. 
This phase requires two months of daily doses of antituberculosis drugs. 
Recommended regimens include 2SHRZ (daily streptomycin, isoniazid, rifampicin and 
pyrazinamide for two months), 2EHRZ (daily ethambutol, isoniazid, rifampicin and 
pyrazinamide for two months) and 2HRZ (daily isoniazid, rifampicin and pyrazinamide 
for two months) (Ministry of Health Malaysia, 2002). 
1.1.7(c)(ii) Maintenance phase 
During the maintenance phase, two or three drugs are usually gtven 
intermittently. This phase is required to eliminate persisting mycobacteria and prevent 
relapse (Kasper DL eta/, 2005). 
This phase requires at least another four months of intermittent antituberculosis 
medications, and may be extended for severe forms of extrapulmonary tuberculosis and 
immunocompromised patients. 
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The available regimens include 4H2R2 (twice-weekly isoniazid and rifampicin 
for four months), 4S2H2R2 (twice-weekly streptomycin, isoniazid and rifampicin for 
four months), 4HR (daily isoniazid and rifampicin for four months), 4H3R3 (thrice-
weekly isoniazid and rifampicin for four months) and 4S3H3R3 (thrice-weekly 
streptomycin, isoniazid and rifampicin for four months) (Ministry of Health Malaysia, 
2002). 
1.1.8 Monitoring Response and Compliance 
1.1.8(a) Treatment Response 
In order to monitor sputum conversion and treatment outcome, it is 
recommended that all patients who are initially sputum smear-positive to repeat sputum 
smears examination at the end of the second month of treatment. Additional sputum 
smears are taken at the fourth month and at the end of the regimens (Ministry of Health 
Malaysia, 2002). 
Patients who do not achieve sputum conversion by two months will require an 
extended treatment. Smear positives documented after five months are indicative of 
treatment failure (Kasper DL et al, 2005). 
1.1.8(b) Patient's Compliance 
Compliance is very important in the management of tuberculosis patients. 
Patient's non-compliance is the main cause of treatment failure as well as the 
emergence of multidrug-resistant tuberculosis. A very high treatment completion rate 
can be achieved by adequate patient education. Directly observed treatment, short-
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course therapy (DOTS) has been shown to be feasible and highly successful towards 
achieving the objective of a 95 percent cure rate (Ministry of Health Malaysia, 2002). 
1.1.9 Drug Toxicity 
During treatment, patients should be monitored for drug adverse effects and 
toxicity, the most common being drug-induced hepatitis. 
1.1.9(a) Antituberculosis Drugs and Adverse Effects 
Antituberculosis drugs are known to have many adverse effects. Some are mild 
and transient; others are potentially hazardous and fatal. 
1.1.9(a)(i) Isoniazid 
The most important adverse effect of isoniazid is hepatotoxicity. This includes 
asymptomatic elevation of aminotransferases, clinical hepatitis and fatal hepatitis. These 
will be further discussed in the next section. 
Approximately 20 percent of patients taken isoniazid develop anti-nuclear 
antibodies, in which less than one percent develop clinical lupus erythematosus that 
requires drug discontinuation. Other adverse effects include hypersensitivity reactions 
such as fever, rash, Stevens-Johnson syndrome, haemolytic anaemia and vasculitis 
which are rare (Blumberg HM et al, 2003). 
Isoniazid may also cause peripheral neurotoxicity which is dose-related and is 
uncommon (less than 0.2%) at conventional doses (Onnerod LP & Horsfield N, 1996). 
The risk is increased in persons with other conditions that may be associated with 
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neuropathy such as nutritional deficiency, diabetes, HN infection, renal failure and 
alcoholism. Pyridoxine supplementation is recommended to help prevent this 
neuropathy (Snider DE, 1980). 
1.1.9(a)(ii) Rifampicin 
Apart from hepatotoxicity, rifampicin may cause cutaneous reactions. Pruritis 
with or without rash may occur in as many as 6 percent of patients but is generally self-
limited (Villarino ME et al, 1997). 
Gastrointestinal reactions such as nausea, anorexia and abdominal pain are rarely 
severe enough to discontinue the drug (Villarino ME et al, 1997). Orange discolouration 
of bodily fluids (sputum, urine, sweat and tears) is a universal effect of the drug, and 
patients should be warned beforehand (Blumberg HM et al, 2003). 
Severe immunologic reactions such as thrombocytopenia, haemolytic anaemia, 
acute renal failure, and thrombotic thrombocytopenic purpura may also occur rarely, in 
less than 0.1 percent of patients (LeeC-H & Lee C-J, 1989). 
1.1.9(a)(iii) Pyrazinamide 
Pyrazinamide may cause nausea and mild anorexia at standard dose (Blumberg 
HM et al, 2003). Polyarthralgias may occur in up to 40 percent of patients receiving 
daily doses of pyrazinamide, but rarely requires drug adjustment or discontinuation 
(Jenner PJ eta/, 1981). 
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Asymptomatic hyperuricaemia is an expected effect of pyrazinamide and is 
generally without adverse consequences (Combs DL et al, 1990). Acute gout is rare 
except in patients with pre-existing gout, and generally a contraindication to the use of 
pyrazinamide (Blumberg HM eta/, 2003). 
An effect of hepatotoxicity is discussed in the following section. 
1.1.9(a)(iv) Ethambutol 
The most important adverse effect of ethambutol is retrobulbar neuritis. This is 
manifested by decreased visual acuity or decreased red-green colour discrimination that 
may affect one or both eyes. The effect is dose related, with minimal risk at daily dose 
of 15 mg/kg. The risk is higher at higher doses given daily (18% of patients receiving 
more than 30 mg/kg per day) and in patients with renal insufficiency (Blumberg HM et 
al, 2003). 
Rarely ethambutol can cause peripheral neuritis (Tugwell P & James SL, 1972). 
Cutaneous reactions requiring discontinuation of the drug occur in 0.2-0. 7 percent of 
patients (Doster Bet al, 1973). 
1.1.9(a)(v) Streptomycin 
The most important adverse reaction caused by streptomycin is ototoxicity, 
including vestibular and hearing disturbances. The risk is increased with age and 
concomitant use of loop diuretics (Blumberg HM et al, 2003). 
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Nephrotoxicity can also occur but less compared to amikacin, kanamycin or 
capreomycin (Appel GB & Neu HC, 1977). Streptomycin, also relatively commonly 
causes circumoral parasthesias immediately after injection (Blumberg HM et al, 2003). 
1.1.9(b) Monitoring of Drug Toxicity 
Where facilities are available, all patients should have baseline measurements of 
liver enzymes, serum bilirubin, serum creatinine, blood urea and a full blood count. The 
purpose of these baseline tests is to detect any abnormality that would necessitate 
modification of the treatment regimen. 
Patients with pre-existing liver disease or conditions such as alcoholism known 
to potentiate hepatotoxicity of antituberculosis drugs should have regular monitoring of 
liver function especially during the first few months of therapy. 
All patients should be monitored clinically for adverse reactions during the 
period of chemotherapy. Routine laboratory monitoring for asymptomatic patients is not 
necessary. If symptoms suggesting drug toxicity occur, appropriate laboratory testing 
should be performed to confirm such toxicity (Ministry of Health Malaysia, 2002). 
t.1.9(c) Management of Drug Toxicity 
Minor side effects, such as gastrointestinal intolerance are best managed by 
reassurance and symptomatic treatment. The most common serious drug toxicity is 
hepatitis. Patients who develop symptoms of liver dysfunction such as nausea, vomiting, 
anorexia and abdominal pain during therapy should have their treatment stopped 
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immediately. Many of them may be successfully restarted on the same drugs, when liver 
functions return to normal (Ministry of Health Malaysia, 2002). 
Patients who develop hypersensitivity reactions, such as rash, to the two most 
potent drugs i.e. isoniazid and rifampicin, may be desensitized later if a suitable regimen 
could not be provided with the other drugs which the patient can tolerate. 
The development of a few conditions contraindicate the further use of the 
causative drug. These include thrombocytopenia, shock and/or renal failure due to 
rifampicin, visual impairment due to ethambutol and eighth cranial nerve damage from 
streptomycin (Ministry of Health Malaysia, 2002). 
1.2 Drug-induced Liver Disease 
1.2.1 Background 
Hepatotoxicity is a potential complication of most prescribed drugs, presumably 
due to the central role of the liver in drug metabolism. In a few cases the adverse liver 
reactions are predictable and dose dependent; however for most drugs liver injury is 
idiosyncratic (Aithal PG & Day CP, 1999). 
Therapeutic drugs remain a significant cause of liver injury and can be associated 
with a variety of histological appearances including chronic hepatitis. The pattern of 
drugs causing liver damage is changing and most often is due to a rare side effect of 
commonly prescribed drugs such as antibiotics and anti-inflammatory drugs, and to 
recently introduced drugs whose hepatotoxicity may not yet be established (Aithal PG 
& Day CP, 1999). 
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1.2.2 Incidence 
Even though many drugs associated with a significant risk of hepatotoxicity have 
been replaced by apparently safer drugs, hepatic drug reactions are being increasingly 
reported, with drugs still accounting for five percent of cases of jaundice admitted to 
hospitals (Friis H & Andreasen PB, 1992). 
Drug-induced hepatic injury is the most frequent reason cited for the withdrawal 
from the market of an approved drug, and it also accounts for more than SO percent of 
the cases of acute liver failure in the United States (Lee WM, 2003). 
1.2.3 Types of Drug Reactions 
Most drugs cause liver injury infrequently. These reactions are considered 
idiosyncratic, occurring at therapeutic doses from 1 in every 1000 patients to 1 in every 
100,000 patients, with a pattern that is consistent for each drug and for each drug class. 
Idiosyncratic reactions are characterized by a variable delay or latency period, ranging 
from 5 to 90 days from the initial ingestion of the drug, and are frequently fatal if the 
drug is continued once the reaction has begun (Lee WM, 2003). 
In contrast, with a drug such as isoniazid, mild injury may disappear despite 
continued use. Others, such as acetaminophen, are dose-dependent hepatotoxic reactions 
(Lee WM, 2003). 
Hepatoxic reactions are dependent on several parameters such as dosage of drug 
received, patient's age, sex, and body mass index which affect metabolism, as well as 
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concurrent use of certain foods and drugs, physiologic changes such as pregnancy, and 
underlying renal or liver disease. 
For reasons that are unclear, women generally predominate among patients with 
drug-induced liver injury, as illustrated in a study in which women accounted for 79 
percent of reactions due to acetaminophen and 73 percent of idiosyncratic drug 
reactions (Ostapowicz G et a/, 2002). 
1.2.4 Mechanisms 
The features of idiosyncratic drug reactions: their rarity, their severity, and their 
resolution despite continued use of the drugs by patients with phenotypes that appear to 
be adaptive, might be explained by a series of events that first involve intracellular 
disruption, cell necrosis (or apoptosis ), followed by activation of the immune sequence 
(Watkins PB, 1992). 
Hepatotoxicity may wax and wane with continuing drug use, implying that 
suppressor or attenuator pathways are active (Watkins PB, 1992). Immune responses, 
once initiated, may be amplified or suppressed by means of the class I and class II 
major-histocompatibility-complex cell-surface receptors. Cell-surface neoantigens may 
be short-lived, but they reappear with continued exposure to the drug (Robin M-A et al, 
1997). 
1.2.5 Clinical Consequences 
The most frequent hepatotoxic drug reactions evoke moderate-to-severe injury to 
hepatocytes with a clinical picture that resembles viral hepatitis, characterized by a 
rapid onset of malaise and jaundice in association with elevated aminotransferases 
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levels. Each drug has its own pattern of injury. If hepatocytes injury predominates, 
aminotransferase levels may be at least five times as high as normal. In cholestatic 
syndromes, elevations of alkaline phosphatase and bilirubin levels predominate. Acute 
liver failure may develop after a week or more of illness, particularly if the offending 
drug is continued (Lee WM, 2003). 
1.2.5(a) Idiosyncratic Reactions 
Idiosyncratic drug reactions made up 20 percent of cases of severe liver injury 
requiring hospitalization in a United States study involving 307 patients at six hospital 
centers (unpublished data). A variety of clinical patterns are observed such as 
hepatocellular with isoniazid, cholestasis with erythromycin and autoimmune reactions 
with lovastatin. The majority of idiosyncratic reactions involve damage to hepatocytes 
throughout the hepatic lobule, with various degrees of necrosis and apoptosis. 
Symptoms of hepatitis occur typically within days or weeks after the initial exposure 
and may continue to evolve even after the offending drug is withdrawn (Lee WM, 2003). 
1.2.5(b) Allergic Reactions 
Some drug reactions have a striking allergic component such as sulfa drugs 
which may induce fever, rash and eosinophilia, and phenytoin may result in fever, 
lymphadenopathy and rash. In most instances, it is slow to resolve that suggests that 
allergens remain on the hepatocytes surface for weeks or months. Rapid recognition of 
toxic effect and immediate discontinuation of the offending drug are important to limit 
hepatic and cutaneous damage (Lee WM, 2003). 
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